ArticleOncotarget2016

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.

Carlo Palmieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.